Frank Diaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Frank Diaz has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Brent L. Fogel
Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA
2 shared publications Catherine Bresee
Biostatistics Shared Resources Cedars‐Sinai Medical Center Los Angeles California USA
2 shared publicationsPablo Avalos
Board of Governors Regenerative Medicine Institute Cedars‐Siniai Medical Center Los Angeles California USA
2 shared publicationsPeggy Allred
Department of Neurology Cedars‐Sinai Medical Center Los Angeles California USA
2 shared publicationsRobert Freundlich
Department of Neurology Olive View‐UCLA Medical Center Sylmar California USA
2 shared publicationsRobert H. Baloh
Board of Governors Regenerative Medicine Institute Cedars‐Siniai Medical Center Los Angeles California USA
2 shared publications
Latest Publications
- 29 September 2025
- Published by Wiley in Annals of Neurology
- Vol. 99 (2) , 418-428
Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment
Objective: The primary lateral sclerosis ( PLS ) consensus diagnostic criteria and functional rating scale ( PLSFRS ) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study ( PLS NHS ) to understand their performance in this prospective cohort. Methods: The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year ( p = 0.001). Interpretation: In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2026;99:418–428
- 29 September 2025
- Published by Wiley in Annals of Neurology
- Vol. 99 (2) , 418-428
Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment
Objective: The primary lateral sclerosis ( PLS ) consensus diagnostic criteria and functional rating scale ( PLSFRS ) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study ( PLS NHS ) to understand their performance in this prospective cohort. Methods: The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year ( p = 0.001). Interpretation: In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2026;99:418–428
- 29 November 2024
- Published by Wiley in Muscle & Nerve
- Vol. 71 (2) , 171-182
Longitudinal Quantitative MRI Provides Responsive Outcome Measures for Early and Late Muscle Changes in ALS
Introduction/Aims: Studies have demonstrated the potential of muscle MRIs to measure disease progression in ALS. However, the responsiveness and utility of quantitative muscle MRIs in an ALS clinical trial remain unknown. This study aimed to determine the responsiveness of quantitative muscle MRIs to measure disease progression in ALS.Methods: Longitudinal quantitative muscle MRIs were obtained in an ALS study that delivered human neural progenitor cells to the spinal cord (NCT02943850). Participants underwent MRIs at baseline, 1, 3, 6, 9, and 12 months. MRI measures included fat fraction (ff), water T2 (T 2m), cross‐sectional area (CSA), and remaining muscle area (RMA). Non‐MRI measures included strength via Accurate Test of Limb Isometric Strength (ATLIS) and the ALSFRS‐R. Standardized response means (SRM) were calculated at 1, 3, 6, and 12 months.Results: Significant increases in muscle FF and decreases in CSA and RMA were seen as early as 1 month from baseline. At 6 months, the most responsive measures were muscle FF (SRMthigh = 1.85, SRMcalf = 1.39), T 2m (SRMthigh = 1.2, SRMcalf = 1.71), CSA (SRMthigh = −1.58, SRMcalf = −1.14), RMA (SRMthigh = −1.77, SRMcalf = −1.28), and strength tested via ATLIS (SRMknee extension = −1.79, SRMknee flexion = −1.3). The ALSFRS‐R was the least responsive at 6 months (SRM = −0.85). Muscle FF and T 2m correlated with ALSFRS‐R leg subscores and MRI measures demonstrated varying degrees of correlation with strength.Discussion: High responsiveness and low variability make quantitative muscle MRI a novel and complementary outcome measure for ALS clinical trials.
- 29 November 2024
- Published by Wiley in Muscle & Nerve
- Vol. 71 (2) , 171-182
Longitudinal Quantitative MRI Provides Responsive Outcome Measures for Early and Late Muscle Changes in ALS
Introduction/Aims: Studies have demonstrated the potential of muscle MRIs to measure disease progression in ALS. However, the responsiveness and utility of quantitative muscle MRIs in an ALS clinical trial remain unknown. This study aimed to determine the responsiveness of quantitative muscle MRIs to measure disease progression in ALS.Methods: Longitudinal quantitative muscle MRIs were obtained in an ALS study that delivered human neural progenitor cells to the spinal cord (NCT02943850). Participants underwent MRIs at baseline, 1, 3, 6, 9, and 12 months. MRI measures included fat fraction (ff), water T2 (T 2m), cross‐sectional area (CSA), and remaining muscle area (RMA). Non‐MRI measures included strength via Accurate Test of Limb Isometric Strength (ATLIS) and the ALSFRS‐R. Standardized response means (SRM) were calculated at 1, 3, 6, and 12 months.Results: Significant increases in muscle FF and decreases in CSA and RMA were seen as early as 1 month from baseline. At 6 months, the most responsive measures were muscle FF (SRMthigh = 1.85, SRMcalf = 1.39), T 2m (SRMthigh = 1.2, SRMcalf = 1.71), CSA (SRMthigh = −1.58, SRMcalf = −1.14), RMA (SRMthigh = −1.77, SRMcalf = −1.28), and strength tested via ATLIS (SRMknee extension = −1.79, SRMknee flexion = −1.3). The ALSFRS‐R was the least responsive at 6 months (SRM = −0.85). Muscle FF and T 2m correlated with ALSFRS‐R leg subscores and MRI measures demonstrated varying degrees of correlation with strength.Discussion: High responsiveness and low variability make quantitative muscle MRI a novel and complementary outcome measure for ALS clinical trials.
- 7 March 2023
- Published by Wiley in Muscle & Nerve
- Vol. 67 (5) , E15-E17
Myofibrillar myopathy presenting with an inclusion bodymyositis‐likephenotype
- 7 March 2023
- Published by Wiley in Muscle & Nerve
- Vol. 67 (5) , E15-E17
Myofibrillar myopathy presenting with an inclusion bodymyositis‐likephenotype
- 18 November 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 64, 74-77
The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage
- 18 November 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 64, 74-77
The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage
- Top Cited PapersOpen Access
- 5 September 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (9) , 1813-1822
Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial
Amyotrophic lateral sclerosis (ALS) involves progressive motor neuron loss, leading to paralysis and death typically within 3–5 years of diagnosis. Dysfunctional astrocytes may contribute to disease and glial cell line-derived neurotrophic factor (GDNF) can be protective. Here we show that human neural progenitor cells transduced with GDNF (CNS10-NPC-GDNF) differentiated to astrocytes protected spinal motor neurons and were safe in animal models. CNS10-NPC-GDNF were transplanted unilaterally into the lumbar spinal cord of 18 ALS participants in a phase 1/2a study (NCT02943850). The primary endpoint of safety at 1 year was met, with no negative effect of the transplant on motor function in the treated leg compared with the untreated leg. Tissue analysis of 13 participants who died of disease progression showed graft survival and GDNF production. Benign neuromas near delivery sites were common incidental findings at post-mortem. This study shows that one administration of engineered neural progenitors can provide new support cells and GDNF delivery to the ALS patient spinal cord for up to 42 months post-transplantation.
- 5 September 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (9) , 1813-1822
Top Cited PapersOpen AccessTransplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial
Amyotrophic lateral sclerosis (ALS) involves progressive motor neuron loss, leading to paralysis and death typically within 3–5 years of diagnosis. Dysfunctional astrocytes may contribute to disease and glial cell line-derived neurotrophic factor (GDNF) can be protective. Here we show that human neural progenitor cells transduced with GDNF (CNS10-NPC-GDNF) differentiated to astrocytes protected spinal motor neurons and were safe in animal models. CNS10-NPC-GDNF were transplanted unilaterally into the lumbar spinal cord of 18 ALS participants in a phase 1/2a study (NCT02943850). The primary endpoint of safety at 1 year was met, with no negative effect of the transplant on motor function in the treated leg compared with the untreated leg. Tissue analysis of 13 participants who died of disease progression showed graft survival and GDNF production. Benign neuromas near delivery sites were common incidental findings at post-mortem. This study shows that one administration of engineered neural progenitors can provide new support cells and GDNF delivery to the ALS patient spinal cord for up to 42 months post-transplantation.
- Open Access
- 15 October 2020
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 7 (11) , 2320-2325
Novel NUDT2 variant causes intellectual disability and polyneuropathy
Exome or genome sequencing was performed to identify the genetic etiology for the clinical presentation of global developmental delay, intellectual disability, and sensorimotor neuropathy with associated distal weakness in two unrelated families. A homozygous frameshift variant c.186delA (p.A63Qfs*3) in the NUDT2 gene was identified in cases 1 and 2 from one family and a third case from another family. Variants in NUDT2 were previously shown to cause intellectual disability, but here we expand the phenotype by demonstrating its association with distal upper and lower extremity weakness due to a sensorimotor polyneuropathy with demyelinating and/or axonal features.
- 15 October 2020
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 7 (11) , 2320-2325
Open AccessNovel NUDT2 variant causes intellectual disability and polyneuropathy
Exome or genome sequencing was performed to identify the genetic etiology for the clinical presentation of global developmental delay, intellectual disability, and sensorimotor neuropathy with associated distal weakness in two unrelated families. A homozygous frameshift variant c.186delA (p.A63Qfs*3) in the NUDT2 gene was identified in cases 1 and 2 from one family and a third case from another family. Variants in NUDT2 were previously shown to cause intellectual disability, but here we expand the phenotype by demonstrating its association with distal upper and lower extremity weakness due to a sensorimotor polyneuropathy with demyelinating and/or axonal features.
- 14 April 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (15_supplem)
NUDT2 Associated Syndrome with Developmental Delay and Peripheral Neuropathy. (1629)
- 14 April 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (15_supplem)
NUDT2 Associated Syndrome with Developmental Delay and Peripheral Neuropathy. (1629)